These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm. Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867 [TBL] [Abstract][Full Text] [Related]
6. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184 [TBL] [Abstract][Full Text] [Related]
7. Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations. Hartmann L; Haferlach C; Meggendorfer M; Kern W; Haferlach T; Stengel A Genes Chromosomes Cancer; 2019 Oct; 58(10):698-704. PubMed ID: 30994218 [TBL] [Abstract][Full Text] [Related]
8. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959 [TBL] [Abstract][Full Text] [Related]
9. Progression in Myeloid Neoplasms: Beyond the Myeloblast. Faria C; Tzankov A Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015 [TBL] [Abstract][Full Text] [Related]
10. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116 [TBL] [Abstract][Full Text] [Related]
11. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864 [TBL] [Abstract][Full Text] [Related]
12. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933 [TBL] [Abstract][Full Text] [Related]
13. Mutation in TET2 in myeloid cancers. Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426 [TBL] [Abstract][Full Text] [Related]
14. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910 [TBL] [Abstract][Full Text] [Related]
15. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Churpek JE; Pyrtel K; Kanchi KL; Shao J; Koboldt D; Miller CA; Shen D; Fulton R; O'Laughlin M; Fronick C; Pusic I; Uy GL; Braunstein EM; Levis M; Ross J; Elliott K; Heath S; Jiang A; Westervelt P; DiPersio JF; Link DC; Walter MJ; Welch J; Wilson R; Ley TJ; Godley LA; Graubert TA Blood; 2015 Nov; 126(22):2484-90. PubMed ID: 26492932 [TBL] [Abstract][Full Text] [Related]
16. FLT3 mutations in myeloproliferative neoplasms: the Beaumont experience. Williams L; Kelley HH; Meng X; Prada A; Crisan D Diagn Mol Pathol; 2013 Sep; 22(3):156-60. PubMed ID: 23846442 [TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255 [TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105 [TBL] [Abstract][Full Text] [Related]
19. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes. Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277 [TBL] [Abstract][Full Text] [Related]
20. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. DiFilippo EC; Coltro G; Carr RM; Mangaonkar AA; Binder M; Khan SP; Rodriguez V; Gangat N; Wolanskyj A; Pruthi RK; Chen D; He R; Viswanatha DS; Lasho T; Finke C; Tefferi A; Pardanani A; Patnaik MM Leukemia; 2020 Sep; 34(9):2519-2524. PubMed ID: 32060405 [No Abstract] [Full Text] [Related] [Next] [New Search]